Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with articular and extra-articular manifestation, and it may be associated with systemic effects. 1 Etiology of RA remains unknown. Although
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the impact of genetic factors is obvious, the genetic basis is not sufficient to explain the triggering of the immune insult in RA patients. 2 RA is associated with a variety of different kidney disorders. The reported prevalence of kidney disease in patients with RA ranges from 5% to 50%, reflecting wide variations in the diagnostic criteria and definitions of renal disease. Furthermore, different study designs can affect the percent of renal affection. 3 Regardless of the traditional cardiovascular risk factors for developing chronic kidney disease (CKD) and glomerulonephritis (GN) still RA patients had a higher risk of developing CKD and GN. This increased risk may be related to GN, chronic inflammation, comorbidities, and renal toxicity of any rheumatic drugs. 4 Improvement of clinical and laboratory parameters in rheumatoid kidney affection was achieved in most cases after drug withdrawal and in some cases with immunosuppressant. 5 In patients with amyloid deposition, etanercept treatment reduced proteinuria as well as serum amyloid A. Furthermore, it entailed a decrease in serum creatinine (Cr) in patients with Cr values <2.0 mg/dL at the onset of amyloidosis. 6 
Patient and Methods
Cairo University Hospital is a major hospital and a tertiary referral center serving patients from Cairo and also patients referred from all other governorates of Egypt. We obtained the hospital records of 1896 RA patients for whom a diagnosis was confirmed and fulfilling the 2010 ACR/EULAR RA Classification Criteria between June 2009 and July 2017. Of these RA patients, 376 developed renal affection throughout the follow-up duration. These patients with renal complications were subjected to full history and clinical examination, kidney function, 24-h urinary protein, and kidney biopsy was obtained, and we analyzed the results of these renal biopsies.
All renal biopsy specimens were evaluated by both light and immune fluorescence microscopes by specialized nephropathology team in the pathology department according to the following standard methods.
Light microscopy
Briefly, kidney biopsy specimens were fixed in buffered formalin, dehydrated in graded alcohols, and embedded in paraffin using standard techniques. Serial 3-mm thick sections were cut and treated with hematoxylin and eosin, Jones methenamine silver, Masson's trichrome, or periodic acid-Schiff reagent. Pathological diagnosis of granulomatous interstitial nephritis depended on detection of interstitial nephritis, in which the inflammatory infiltrate contained at least one aggregate of epithelioid histiocytes admixed with lymphocytes with or without multi-nucleated giant cells. To differentiate amyloid from other hyaline deposits, Red Congo stain was used. Amyloid material has high affinity for Congo red stain and if present; amyloid deposits have a characteristic green birefringence when examined with polarized light.
Immunofluorescence microscopy
Samples were transported in Michel media, washed in buffer, and frozen in a cryostat. Sections, cut at 5 mm, were rinsed in buffer and reacted with fluorescein-tagged polyclonal rabbit antihuman antibodies to IgG, IgA, IgM, C3, C4, C1q, fibrinogen, k or l light chains (Dako, Carpenteria, CA; Kent Laboratories, Bellingham, WA, USA) for 1 h and rinsed; a cover slip was applied using aqueous mounting media.
Statistical Analysis
Data were coded and entered using the Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM Corp., Armonk, NY, USA). Data were summarized using mean, standard deviation (SD), median, minimum and maximum in quantitative data, and using frequency (count) and relative frequency (percentage) for categorical data. For comparing categorical data, Chi-square test was performed. Exact test was used instead when the expected frequency is <5. P <0.05 were considered as statistically significant.
Results
Our study included 376 RA with kidney affection, 180 females, 196 males, age range from 24 to 62 years with a mean of 42.3 ± 8.78, disease duration range from 13 to 56 months with a mean of 31.2% ± 7.96.25% of them were smokers. About 23.9% of our patients were diabetics, 31.4% of our patients were hypertensive, and 17.3% of our patients had interstitial lung disease.
All our patients were on methotrexate with a dose ranging from 12.5 mg/w to 25 mg/w, low dose steroid 7.5 mg/d, and nonsteroidal antiinflammatory drugs (NSAIDs), in addition to the previous medication 79.3% of our patients were on leflunomide, 20.7% were on hydroxychloroqine, 6.9% were on etanercept, 5.9% were on infliximab.
Renal affection of our patients started before treatment initiation in 10.4%, and in 89.6% after starting treatment. Renal presentation in our patients were as follows; nephrotic syndrome (NS) was present in 33.5%, persistent subnephrotic proteinuria was present in 12.2%, persistent proteinuria and recurrent hematuria was present in 13.3%, acute nephritis was present in 23.9%, recurrent hematuria after the exclusion of urological causes was present in 7.4%, and impaired renal function with Cr >1.5 mg/dL was present in 10.6% ( Figure 1 ). As regards laboratory findings, the mean and SD of Cr was 1.46 ± 1.31 mg/dL, serum calcium mean and SD was 8.17 ± 0.62 mg/dL, serum phosphorus mean and standard deviation (S)D was 3.9 ± 0.81 mg/dL, hemoglobin mean and SD was 10.2 ± 2.7g/dL, serum albumin mean and SD was 3.22 ± 0.49 mg/dL, 24-h urinary protein mean and SD was 2.8 ± 1.08 g/dL. Hematuria was found in 7.4% of our patients; 23.9 % of our patients had casts in urine.
Renal biopsy of our patients revealed the following: 1. Glomeular affection: 28.1% of our patients had amyloidosis, 19.1% of our patients had mesangioproliferative affection, 6.1% of our patients had membranous affection, crescent form was found in 16.8% of our patients, 18.6% of our patients had focal segmental glomerulosclerosis (FSGS), and minimal change picture was found in 11.7% of our patients (Table 1 ). 2. Tubulointerstitial affection: 17% of our patients had amyloidosis, 2.1% of our patients had acute nephritis, 3.5% of our patients had chronic nephritis, acute tubular necrosis (ATN) was found in 4.3% of our patients, and 38.8% of our patients had interstitial fibrosis and tubular atrophy (IF/TA was mild in 50% of them, moderate in 42.5% of them, and marked affection was found in 7.5%) ( Table 2 ). 3. Vascular affection: 13% of our patients had amyloidosis, 17.6% of our patients had arterial hyalinosis, 2.9% of our patients had thrombotic microangiopathy, vasculitis was found in 4.8% of our patients, and 9.9% of our patients had arterial intima fibrosis (Table 1 ). Renal affection of our patients started before treatment initiation in 10.4%. About 61.5% of this subset of patients had crescentic form, 15.4% had amyloidosis, 7.8% had mesangioproliferative affection, 5.1% had membranous affection, 5.1% had FSGS, and minimal changes was found in 5.1% of this subset of patients.
Persistent subnephrotic proteinuria was present in 12.2%. About 82.6% of this subset of patients had minimal changes, while FSGS was found in 17.4% of this subset of patients. Persistent proteinuria and recurrent hematuria were present in 13.3%. About 100% of this subset of patients had mesangioproliferative affection.
Crescentic GN was found in 16.8% of our patients. Sixty-three percent of this subset of patients had cellular crescents. Twenty-seven percent had fibrocellular crescents. Fibrous crescents were found in 10% of this subset of patients. About 71.4% of this subset of patients was antineutrophil cytoplasmic antibodies (ANCA) negative, while 15.9% of this subset of patients had ANCA-c and 12.7% had ANCA-p. C3 and C4 were done in 100% of this subset of patients which were consumed in 6.3% of this subset of patients.
About 28.1% of our patients had amyloidosis. The average age in these subsets of the patient was 41.9 (24-62 ± 8.9).
There was a statistically significant difference in the incidence of membranous nephropathy between patients who took leflunomide and those who did not also we found the same result in patients taking hydroxychloroquine where there was statistically significant difference in the incidence of membranous nephropathy between patients who took hydroxychloroquine and those who did not (Table 2) . Etanercept in our study seems not to be related to any form of renal affection, while infliximab seems to be related to focal segmental sclerosis and amyloidosis of tubulointerstial type, as there was statistically significant difference in the incidence of focal segmental sclerosis and amyloidosis of tubulointerstial type between patients who took infliximab and those not (Table 3) .
Discussion
RA is a widespread disease and its renal involvement, is relatively common, and it is clinically significant because it worsens the course of the primary disease and mortality. 7 In RA kidney is the most common affected organ with clinical presentation characterized by proteinuria (often nephrotic range) and micro-hematuria followed by chronic renal failure. This condition is well known as a rheumatoid nephropathy (rheumatoid GN), which is mediated by an immunological inflammation and by the nephrotoxic effects of numerous drugs which are usually used in treatment of RA, such as NSAID 8 This is consistent with our study where our patients present with NS, persistent subneph-rotic proteinuria, persistent proteinuria with recurrent hematuria , acute nephritis, recurrent hematuria, and impaired renal function with Cr >1.5 mg/dL, with the most common presentation was the NS. NS represent about onethird of renal affection in our patients. RA and renal disease often coincide with each other. The renal toxicity of antirheumatic drugs (for example, NSAID or cyclosporine toxicity), secondary renal disease which induced by the chronic inflammatory process (especially renal amyloidosis) and potentially, renal manifestations of the primary disease process, are an important differential diagnoses. 9 In this study, most of our patients started to develop renal affection mainly after starting RA treatment by 89.6%, and hence, this may raise the possibility of the major role of the medication in renal affection, we study the effect of different medication added to baseline treatment of methotrexate, low dose steroids, and NSAIDs to detect the role of other anti-rheumatic drugs when added to them. The era of modern medicine, patients are exposed to a wide variety of drugs for diagnostic and therapeutic purposes. Unfortunately, many of these agents cause adverse drug effects accompanied with systemic toxicity, including impairment of renal function. Nephrotoxicity results in serious clinical syndromes. 10 Leflunomide has, in contrast to many other diseasemodifying agents in RA, no known renal side effects. Leflunomide has been incriminated once as causing IgA GN 11 and anti-glomerular basement membrane disease in two RA patients. 12 Leflunomide in this study was related to membranous kidney affection in RA patients. Chloroquine and the chemically related hydroxychloroquine are antimalarials used to treat patients with rheumatic disorders. The incidental morphologic consequence of chloroquine usage, in the form of accumulation of lipid inclusions in podocytes, has been documented. In 2003, a case describing significant deterioration of renal function due to a high cumulative dose of the drug was described. 13 Hydroxychloroquine in the study was related to membranous kidney affection. These findings warrant close follow-up of kidney function to those kept on these medications for long time. Tumor necrosis factor-alpha (TNF-α) is a major pro-inflammatory cytokine in many 14 Stokes et al suggested the pathogenic role for anti-TNF-α agents in induction of RA-related nephropathy. Taken together, the clinical, serologic, and pathologic findings in their cases suggest a pathogenic role for anti-TNF-α therapy-related immune dysregulation. 15 In our study, we found that patients on etanercept had no kidney affection while those on infliximab develops focal segmental sclerosis and amylodosis of tubulointerstitial type, and this may be due to ethnic variation and patient types. A study of renal biopsy specimens indicated that mesangial GN is the predominant histopathologic finding in RA, followed by amyloidosis, membranous nephropathy, focal proliferative GN, minimal-change nephropathy and acute interstitial nephritis. 16 AA amyloidosis is one of most severe complications of RA. It leads to rapid end-stage renal failure; renal dialysis is often unable to prevent early death. 17 In our study, we found different types of renal affection the most common presentation in our study was amylodosis either the golmerular one followed by mesangial proliferative, followed by amylodosis the tubulointerstial type, followed by arteriolar hylanosis. In our study, renal biopsies were glomeular amyloidosis (28.1%), Mesangioproliferative (19.1%), membranous (6.1%), crescent (16.8%), FSGS (18.6%), and minimal changes (11.7%), tubulointerstial amyloidosis (17%), acute nephritis (2.1%), chronic nephritis (3.5%), ATN (4.3%), IF (38.8%), and TA (IF/TA was mild in 50% of them, moderate in 42.5% of them, and marked affection was found in 7.5%), vascular amyloidosis (13%), arterial hylanosis (17.6%), thrombotic microangiopathy (2.9%), vasculitis (4.8%), and arterial intima fibrosis (9.9%).
Conclusion
Kidney involvement in RA is not a rare complication. Any type of histopathological changes can present with amylodiosis on top of the list. Hydroxychloroquine and leflunomide is accused in membranous nephropathy. Infliximab is associated with focal segmental sclerosis and amyloidosis of tubulointerstial type and eteneracept appear to be safe as regards kidney affection.
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